STEMLINE THERAPEUTICS INC has a total of 43 patent applications. It increased the IP activity by 300.0%. Its first patent ever was published in 2007. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are JIANG XI, NO 309 HOSPITAL OF PLA and BERGSTEIN IVAN.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 12 | |
#2 | EPO (European Patent Office) | 10 | |
#3 | WIPO (World Intellectual Property Organization) | 10 | |
#4 | Canada | 4 | |
#5 | Japan | 4 | |
#6 | Australia | 1 | |
#7 | Hong Kong | 1 | |
#8 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Enzymes | |
#5 | Analysing materials | |
#6 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Bergstein Ivan | 37 |
#2 | Cirrito Thomas P | 26 |
#3 | Brooks Christopher | 16 |
#4 | Ivan Bergstein | 4 |
#5 | Thomas P Cirrito | 4 |
#6 | Poradosu Enrique | 2 |
#7 | Cirrito Thomas | 2 |
#8 | Crabbe Thomas Bartholomew | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020112642A1 | Improved methods of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate | |
AU2019370284A1 | Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents | |
WO2020056269A1 | Methods for treating centronuclear myopathy | |
WO2019210179A1 | Methods of treating an autoimmune disease with a human interleukin-3 (il-3)-diphtheria toxin conjugate (dt-il3) | |
EP2849772A1 | Cancer stem cell targeted cancer vaccines | |
US2015079135A1 | Methods for treating and monitoring the status of cancer | |
TW200819456A | Cancer therapy with cantharidin and cantharidin analogs | |
WO2008030538A2 | Cancer stem cell-targeted cancer therapy |